Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Income from Continuing Operations (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Income from Continuing Operations for 5 consecutive years, with 16370000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 2.39% to 16370000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 72926000.0, a 19.28% decrease, with the full-year FY2024 number at 71577000.0, down 97.58% from a year prior.
  • Income from Continuing Operations was 16370000.0 for Q3 2025 at Werewolf Therapeutics, up from 17993000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5074000.0 in Q2 2023 to a low of 20306000.0 in Q4 2024.
  • A 5-year average of 13813631.58 and a median of 14875000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 65.89% in 2023, then tumbled 260.84% in 2024.
  • Werewolf Therapeutics' Income from Continuing Operations stood at 17918000.0 in 2021, then skyrocketed by 33.03% to 12000000.0 in 2022, then grew by 17.77% to 9868000.0 in 2023, then crashed by 105.78% to 20306000.0 in 2024, then grew by 19.38% to 16370000.0 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Income from Continuing Operations are 16370000.0 (Q3 2025), 17993000.0 (Q2 2025), and 18257000.0 (Q1 2025).